ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 109 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 1.92 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,910,356 | -28.9% | 194,933 | 0.0% | 0.01% | -27.3% |
| Q2 2023 | $5,499,060 | +64.0% | 194,933 | 0.0% | 0.01% | +57.1% |
| Q1 2023 | $3,352,848 | -14.6% | 194,933 | 0.0% | 0.01% | -22.2% |
| Q4 2022 | $3,925,951 | +19.4% | 194,933 | +28.4% | 0.01% | +12.5% |
| Q3 2022 | $3,289,000 | +40.1% | 151,853 | +81.8% | 0.01% | +33.3% |
| Q2 2022 | $2,347,000 | -39.1% | 83,526 | 0.0% | 0.01% | -25.0% |
| Q1 2022 | $3,854,000 | -45.1% | 83,526 | 0.0% | 0.01% | -38.5% |
| Q4 2021 | $7,021,000 | +204.7% | 83,526 | +141.5% | 0.01% | +160.0% |
| Q3 2021 | $2,304,000 | -32.9% | 34,580 | -46.5% | 0.01% | -28.6% |
| Q2 2021 | $3,436,000 | +854.4% | 64,580 | +678.1% | 0.01% | +600.0% |
| Q1 2021 | $360,000 | -16.5% | 8,300 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $431,000 | – | 8,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |